Comparative Pharmacology
Head-to-head clinical analysis: TRINALIN versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRINALIN versus XYZAL.
TRINALIN vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine/Decongestant
Antihistamine